PRN: Groundbreaking Chemistry Research Recognized Through the Reaxys® PhD Competition
Groundbreaking Chemistry Research Recognized Through the ReaxysÂ® PhD Competition
NEUCHÃTEL, Switzerland, December 15, 2011 /PRNewswire/ --
3rdÂ Annual ReaxysÂ®Â PhD PrizeÂ launched to award original and innovative research in organic, organometallic and inorganic chemistry
ReaxysÂ®, a leading workflow solution that provides extensive information on chemical compounds, related physical and pharmacological properties, today announced the launch of the 3rd Annual ReaxysÂ® PhD Prize. The competition is for Chemistry students currently studying for a PhD or having completed a PhD within the last 12 months.
The prize will be awarded to the candidates that best demonstrate excellence in methodology and approach in a peer-reviewed publication. Three prize winners will each receive a check for $2000 and will be invited to present their research at the Winners' Symposium.
The 2012 Winners' Symposium will be held at the American Chemical Society (ACS) Fall Meeting in Philadelphia, August 19- 23, 2012. The Symposium is sponsored by the ACS Division of Inorganic Chemistry and co-sponsored by the ACS Division of Organic Chemistry. The three winners will each present their papers at the symposium alongside presentations given by two members of the ReaxysÂ® Advisory Board - Professor Barry M. Trost (Stanford University) and Professor Dr Martin Jansen (Max Planck Institute, Stuttgart).
"After two successful years, the ReaxysÂ® PhD Prize is already establishing itself as the premier international prize for PhD Chemists," said David Evans PhD, Scientific Affairs Director at Elsevier Properties SA. Â "Prior winners and finalists represent the best cutting edge chemistry research being performed by young chemists at some of the world's top universities. We are excited to see how well this year's candidates will measure up in terms of research excellence, rigor and innovation - qualities to which the whole ReaxysÂ® team is also committed to achieve."
All entries will be reviewed by a review board of leading international chemists, chaired by the following members of the ReaxysÂ® Advisory Board:
Submissions will be reviewed based upon originality, innovation, importance to the field, applicability, rigor of approach and publication quality.
All submissions must include a PhD Supervisor letter of recommendation, a CV and a representative peer-reviewed piece of published research. Entries should be submitted by February 15, 2012 here: http://prize.reaxys.com
ReaxysÂ® is a registered trademark ownedÂ andÂ protected by Elsevier Properties SA and used under license.
About Elsevier Properties SA
Elsevier Properties SA is a center of excellence within Reed Elsevier for the management of intellectual property. Elsevier Properties SA owns the PharmaPendium and ReaxysÂ® databases. Trademarks including ReaxysÂ®, PharmaPendium™ and The LancetÂ® are owned and protected by Elsevier Properties SA and used under license.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care ins! titutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV; the combined market capitalization of the two parent companies is approximately Â£12bn/€13bn. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Company Codes: LSE:REL, NYSE:RUK, NYSE:ENL